fda approved glp-1 gip medications 2025 for Weight Loss: Semaglutide vs Tirzepatide vs Retat – Revolution Health & Wellness GLP-1 Pipeline Update: August 2025

Clinicians and educators are encouraged to explore the potential of CGM for adults not using insulin

Starting semaglutide may cause temporary vision changes, especially in people with diabetic eye disease

For instance, Wegovy (specifically approved for weight management) has demonstrated impressive results in clinical trials, with many patients losing substantial percentages of their body weight

a number that may prompt a few raised eyebrows in both retina and diabetes clinics

The most common side effects, gastrointestinal symptoms, affect a large percentage of users but are generally manageable and often improve with time

PMCID: PMC5890906